These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 18331607

  • 1. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
    Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):737-44. PubMed ID: 18331607
    [Abstract] [Full Text] [Related]

  • 2. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA, Horowitz M, Deacon CF, Feinle-Bisset C, Rayner CK, Luscombe-Marsh N, Little TJ.
    Am J Physiol Endocrinol Metab; 2014 Nov 01; 307(9):E830-7. PubMed ID: 25231186
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J.
    J Clin Endocrinol Metab; 2009 Mar 01; 94(3):846-52. PubMed ID: 19088168
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.
    J Clin Endocrinol Metab; 2009 Jan 01; 94(1):81-8. PubMed ID: 18957505
    [Abstract] [Full Text] [Related]

  • 9. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B.
    Diabetes Obes Metab; 2014 Sep 01; 16(9):812-8. PubMed ID: 24612221
    [Abstract] [Full Text] [Related]

  • 10. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
    Landersdorfer CB, He YL, Jusko WJ.
    Br J Clin Pharmacol; 2012 Mar 01; 73(3):373-90. PubMed ID: 22442825
    [Abstract] [Full Text] [Related]

  • 11. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL, Valencia J, Zhang Y, Schwartz SL, Ligueros-Saylan M, Foley J, Dole WP.
    Br J Clin Pharmacol; 2010 Jul 01; 70(1):34-42. PubMed ID: 20642545
    [Abstract] [Full Text] [Related]

  • 12. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.
    Diabetes Care; 2008 Jan 01; 31(1):30-5. PubMed ID: 17947341
    [Abstract] [Full Text] [Related]

  • 13. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
    El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.
    J Clin Endocrinol Metab; 2007 Nov 01; 92(11):4165-71. PubMed ID: 17698900
    [Abstract] [Full Text] [Related]

  • 14. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.
    Horm Metab Res; 2007 Nov 01; 39(11):826-9. PubMed ID: 17992639
    [Abstract] [Full Text] [Related]

  • 15. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.
    Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M.
    Am J Physiol Gastrointest Liver Physiol; 2002 Mar 01; 282(3):G424-31. PubMed ID: 11841992
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M, Saji T, Mita S, Kulmatycki K, He YL, Furihata K, Sekiguchi K.
    Int J Clin Pharmacol Ther; 2013 Aug 01; 51(8):641-51. PubMed ID: 23782587
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
    He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K.
    Int J Clin Pharmacol Ther; 2010 Sep 01; 48(9):582-95. PubMed ID: 20860912
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.